HAP in a nut shell , high quality medicine approach
episode one (meropenem resistance ,tips and tricks)
...........
1-empirical antibiotic :
you have to cover MRSA and psuedomonas in most patients
use vancomycin for MRSA
use anti pseudomonal (piperacillin/tazobactam , ceftazidime or carbapenem )
for simplification let us say (vancomycin+meropenem)
2- routine sputum culture is mandatory in HAP (result is expected with in 72 h ideally )
3-nasal swab for MRSA(rapid molecular assays) in every patient on empirical vancomycin (result is expected in 48h) , stop if negative as NPV is 97%
............
Clinical re-evaluation within 48 hours
if clinical improvement with in 48h is noticed then continue on the same regimen , update according the results
if there is no clinical improvement after 48 h , change the antibiotic
if negative swab = no need for vancomycin
call the microbiologist : if the organism is gram positive cocci , no need for escalation of anti pseudomonals (I recommend against premature cessation of anti pseudomonal considering the risk of poly polymicrobial infection)
if it gram negative bacilli , then you have to add a second anti-pseudomonal
To achieve mechanistic synergy and avoid dual beta lactam redundancy ,high-dose Amikacin ( aminoglycoside disrupting the 30S ribosomal subunit) or fluoroquinolone ( Levofloxacin)can be used as add on therapy (not as a monotherapy)
NB: Amikacin should be considered , due to poor epithelial lining fluid (ELF) penetration in the lungs
High-dose Amikacin is specifically optimized here to achieve synergistic alveolar concentrations, whereas Levofloxacin is reserved as a non-nephrotoxic alternative for patients with compromised baseline renal function."
NB : هنا هنزود مؤقتا تكة للمستوى المتقدم
Efflux Traps: Secondary efflux pump systems (like MexCD-OprJ) can heavily complicate the fluoroquinolone alternative choice. If MexCD-OprJ is upregulated, fluoroquinolones cannot be used at all as they are actively extruded, and you must pivot away from them entirely to a different non- beta lactam class, accept the renal risks of Amikacin with strict therapeutic drug monitoring
هنتكلم عن النقطة دي بتوسع فى مكانها بإذن الرحمن
..................
Decoding the 72-Hour Susceptibility Report
By day three, definitive antimicrobial susceptibility testing yields minimum inhibitory concentration (MIC) values
MIC less 2= Susceptible
4-8= intermediate resistance
more 8= resistance
resistence may be either due to enzymatic hydrolysis (Ambler Class A, B, or D carbapenemases) or non-enzymatic permeability defects
"NB:
The classic, highly common paradox is Imipenem-Resistant / Meropenem-Susceptible .this carbapenem susceptibility discordance is due to loss of the OprD porin channel which completely eliminates Imipenem influx, causing absolute Imipenem resistance. However, Meropenem is only partially dependent on OprD and relies heavily on efflux pumps (MexAB-OprM)
.....
To resolve these overlapping mechanisms without relying on delayed genetic testing we use the Inhibitor-based disk potentiation tests
(A) EDTA Chelation:
Unmasking Metallo- beta-Lactamases (MBLs)
If adding ethylenediaminetetraacetic acid (EDTA) restores the zone of inhibition around a carbapenem disc(more than 5 mm), the pathogen is confirmed to produce an Ambler Class B MBLs (e.g., NDM, VIM, or IMP).
MBL-producing strains are universally resistant to all standard carbapenems, as well as modern serine-targeting beta -lactamase inhibitor combinations like Ceftazidime/Avibactam and Imipenem/Relebactam
Because Monobactams are structurally immune to MBL-mediated hydrolysis, the optimal targeted therapeutic maneuver is the simultaneous co-administration of separate Ceftazidime/Avibactam and Aztreonam
(B)Boronic Acid Chelation
expansion of the zone of inhibition upon the addition of boronic acid indicates the inhibition of serine-based Class A (KPC) or hyper-produced Class C (AmpC)
but this is not that easy
⬇️⬇️KEEP READING⬇️⬇️
August 29, 2026 98 1 1
